Causality assessment of adverse events by healthcare professionals in an academic hospital setting: a descriptive retrospective study

被引:0
|
作者
Corbin, Sonia [1 ,2 ]
Lavallee, Maude [1 ,2 ]
Pradhan, Pallavi [1 ,3 ]
Thibault, Magalie [1 ]
Methot, Julie [1 ,2 ]
Djiokeng, Laura Blonde Guefack [1 ,3 ]
Berard, Anick [4 ,5 ]
Piche, Marie-Eve [1 ,6 ]
Gimenes, Fernanda Raphael Escobar [7 ]
Darveau, Rosalie [1 ]
Cloutier, Isabelle [1 ,2 ]
Leclerc, Jacinthe [1 ,2 ]
机构
[1] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada
[2] Univ Laval, Fac Pharm, Quebec City, PQ, Canada
[3] Univ Quebec Trois Rivieres, Anat Dept, Trois Rivieres, PQ, Canada
[4] CHU St Justine Res Ctr, Montreal, PQ, Canada
[5] Univ Montreal, Fac Pharm, Montreal, PQ, Canada
[6] Univ Laval, Fac Med, Quebec City, PQ, Canada
[7] Univ Sao Paulo, Ribeirao Preto Coll Nursing, Dept Gen & Specialized Nursing, Sao Paulo, SP, Brazil
关键词
causality assessment; pharmacovigilance; adverse drug reactions; hospital; patient safety; DRUG-REACTIONS;
D O I
10.1139/cjpp-2024-0268
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Assessing the causality of a drug product-related adverse event (AE) is a very important aspect of pharmacovigilance. However, it is unclear whether AEs are investigated for causality in a hospital setting. The aims of this study were to (1) evaluate the proportion of AEs for which causality is sought and (2) list the causality assessment (CA) tools used by healthcare professionals. This retrospective study includes 500 randomized patients (125 patients/year) admitted to a tertiary care academic hospital between 2018 and 2021. Electronic medical records were reviewed and relevant variables were extracted: (1) demographic, (2) hospitalization, (3) drug product, (4) AE, and (5) CA. A descriptive analysis was carried out (median, minimum-maximum, proportion) to characterize our sample. The characteristic of our sample was as follows: median age 69 years old (range: 21-96 years), 43.6% female, median comorbidities/patient 4 (0-12), and median hospital stay of 3 days (1-19). We identified a total of 9568 drug products and 2541 AEs, among these, 302 (8.4%) were serious AEs. No CA (n = 0) or CA tools (n = 0) were found in our sample. In this study, we report that no AEs, whether serious or non-serious, were subject to documented CA.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Reporting Rates of Opioid-Related Adverse Events Since 1965 in Canada: A Descriptive Retrospective Study
    Maude Lavallée
    Carolina Galli da Silveira
    Samuel Akinola
    Julie Méthot
    Marie-Eve Piché
    Anick Bérard
    Magalie Thibault
    Jennifer Midiani Gonella
    Fernanda Raphael Escobar Gimenes
    Jacinthe Leclerc
    Drugs - Real World Outcomes, 2022, 9 : 153 - 163
  • [32] Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
    Guimaraes Wiegandt Ceglio, William Queiroz
    Rebeis, Marina Mattos
    Santana, Marcela Ferreira
    Miyashiro, Denis
    Cury-Martins, Jade
    Sanches, Jose Antonio
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2022, 97 (01) : 14 - 21
  • [33] Factors that Motivate Healthcare Professionals to Report Adverse Drug Events: A Systematic Review
    Abjaude S.A.R.
    Mieli S.F.
    Magalhães Z.R.
    Pereira L.R.L.
    Pharmaceutical Medicine, 2017, 31 (1) : 13 - 20
  • [34] Adverse drug events in hospital settings: Reporting & fate at a tertiary academic hospital: Cross-sectional study
    Almetwazi, Mansour
    Alqasem, Mohammed
    AlHadlaq, Tariq
    Aljumayd, Ali
    Alreshedi, Faisal
    Mancy, Wael
    Alqahtani, Nasser
    Alhuwyail, Ghadah
    Alhawassi, Tariq
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 254 - 255
  • [35] Causality Assessment of Adverse Drug Reactions with Antimicrobial Drugs in a Teaching Hospital
    Asir, Prathab A.
    Menon, Rema N.
    Madhavrao, C.
    Babu, Sarath K.
    INDIAN JOURNAL OF PHARMACOLOGY, 2013, 45 : S273 - S273
  • [36] Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study
    Lal, Lincy S.
    Aly, Abdalla
    Le, Lisa B.
    Peckous, Susan
    Seal, Brian
    Teitelbaum, April
    CANCER REPORTS, 2022, 5 (05)
  • [37] Adverse Reactions Associated with Comirnaty® Among Healthcare Professionals: A Cohort Event Monitoring Study in a Portuguese Hospital
    Tavares, I.
    Penedones, A.
    Abrantes, J. R.
    Mendes, D.
    Codeco, C.
    Rigueiro, G.
    Alves, C.
    Marques, F. B.
    DRUG SAFETY, 2022, 45 (10) : 1197 - 1198
  • [38] Global Trigger Tool methodology to detect adverse events: pilot study at Academic Hospital of Udine
    Scarpis, E.
    Degan, S.
    De Corti, D.
    Mellace, F.
    Cocconi, R.
    Farneti, F.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30
  • [39] The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study
    Kim, Jwa Hoon
    Seo, Seyoung
    Kim, Jee Hyun
    Koh, Su-Jin
    Ahn, Yongchel
    Jung, Kyung Hae
    Ahn, Jin-Hee
    Kim, Sung-Bae
    Kim, Tae Won
    Hong, Yong Sang
    Kim, Sun Young
    Kim, Jeong Eun
    Kim, Sang-We
    Lee, Dae Ho
    Lee, Jae Cheol
    Choi, Chang-Min
    Yoon, Shinkyo
    Jeong, Jae Ho
    Kim, Hwa Jung
    Suh, Koung Jin
    Kim, Se Hyun
    Kim, Yu Jung
    Min, Young Joo
    Baek, Jin Ho
    Park, Sook Ryun
    CANCER MEDICINE, 2022, 11 (03): : 705 - 714
  • [40] Preventability, predictability, severity and causality assessment of adverse drug reactions reported from a teaching hospital in chhattisgarh: A retrospective analysis
    Keche, Yogendra
    Gaikwad, Nitin
    Dhaneria, Suryaprakash
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (07) : 2541 - 2545